Minerva Neurosciences | NERV - Interest Expense On Debt


Minerva Neurosciences reported $2.31M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Adma Biologics USD 1.68M 150K Sep/2025
ALKERMES USD 12.28M 7.63M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Bristol-Myers Squibb USD 432M 48M Dec/2025
Cipla INR 140.3M 8.5M Dec/2025
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
J&J USD 18M 290M Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
Takeda JPY 123.63B 40.49B Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025